Development of a Rapid and Confirmatory Method to Identify Ganoderic Acids in Ganoderma Mushrooms by Qi, Ying et al.
METHODS ARTICLE
published: 07 May 2012
doi: 10.3389/fphar.2012.00085
Development of a rapid and conﬁrmatory method to
identify ganoderic acids in Ganoderma mushrooms
Ying Qi
1*, Lingling Zhao
1 and Hao H. Sun
2*
1 Center for Anti-Aging Research, Shanghai R&D, Nu Skin Enterprises, Shanghai, China
2 Center for Anti-Aging Research, Nu Skin Enterprises, Provo, UT, USA
Edited by:
Xiao-Ling Zhu, Peking University
Health Science Center, China
Reviewed by:
Shu-Hui Zhang, Shanghai University
ofTraditional Chinese Medicine, China
Xiao-Ling Zhu, Peking University
Health Science Center, China
*Correspondence:
Ying Qi, Center for Anti-Aging
Research, Shanghai R&D, Nu Skin
Enterprises, No. 116, Building 11,
Lane 572, Bi Bo Road, Shanghai
201203, China.
e-mail: yingqi@cn.nuskin.com;
Hao H. Sun, Center for Anti-Aging
Research, Nu Skin Enterprises, 75
West Center Street, Provo, UT 84601,
USA.
e-mail: hsun@nuskin.com
To examine the composition of lanostanoids in Ganoderma lucidum, we have developed a
liquid chromatography–mass spectrometry (LC–MS) method by using the ganoderic acids
isolated in our laboratory as reference standards.The identity of 14 peaks in the high perfor-
mance liquid chromatogram (HPLC) of G. lucidum has been conﬁrmed. By using the HPLC
retentiontimesoftheseganodericacidsandtheirmassfragmentationpatternsestablished
in this paper, one can use LC–MS to analyze G. lucidum without requiring the reference
standards of these 14 ganoderic acids. Subsequently, only the HPLC–UV method would
be needed to analyze routine samples of G. lucidum.
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INTRODUCTION
In our ongoing investigations of Traditional Chinese Medicine
(TCM) for dietary supplements we are particularly interested
in the medicinal mushroom Ganoderma lucidum (W. Curt.:Fr.)
Karst because it is a rich producer of lanostanoids. This class of
triterpenes has been reported to have distinct pharmacological
activities. These include angiotensin-converting-enzyme inhibi-
tion, anti-HIV action, antinociceptic action, histamine release
inhibition, HMG-CoA reductase inhibition, and liver function
stimulation (Mekenna, 1998). The prevalent usage of G. lucidum
by cancer patients in Asia also persuaded us to further inves-
tigate the active components of G. lucidum. Indeed, we found
that the extract of G. lucidum prepared in our labs induced the
modulation of secretion from normal human peripheral blood
mononuclear leukocytes of cytokines IL-2, IL-4, and IFN-γ (Ma
et al.,2002).
Solvent partitioning and repeated chromatography, followed
by crystallization resulted in the isolation of 32 lanostanoids from
the lipophilic extract of the fruiting body of G. lucidum. These
include six previously unknown oxygenated lanostanoids: 8β,9α-
dihydroganoderic acid J (1), methyl 8β,9 α-dihydroganoderate J
(2), 20-hydroxylganoderic acid G (3)( Ma et al., 2002), ganoderic
acid Sz (4)( Li et al., 2005), 7-oxo-ganoderic acid Z (5), and 15-
hydroxy-ganoderic acid S (6)( Figure 1). Compounds 5 and 6
both exhibited inhibitory activities against HMG-CoA reductase
and acyl CoA-acyltransferase (Li et al., 2006). We have also iso-
lated 26 known lanostanoids, including ganoderic acids I (7) and
C2 (8), 12-deacetylganoderic acid H (9), ganoderic acid G (10),
ganoderenicacidB(11),ganodericacidsB(12),AM1 (13),A(14),
and H (15), ganoderenic acid D (16), ganoderic acids C (17), F
(18), J (19), DM (20), S and Y, methyl ganoderate I, ganoderiols
B and F, ganoderol B, ganodermic acid Q, ganodermenonol, gan-
odermanondiol, ganodermanontriol, lucidone A, and lucidenic A
(Ma et al.,2002;Li et al.,2005,2006; and references cited therein).
Their structures were determined by using 1D and 2D NMR and
MS spectroscopic methods.
Ganodermalucidumhasusuallybeentakenorallyasmushroom
powder or in its extract form,whether as prescribed by TCM doc-
torsorinmodernpillform.Thereisaneedtounderstandthecom-
positionofthenaturalmaterialingested.Liquidchromatography–
mass spectrometry (LC–MS) has been used wildly to characterize
and standardize triterpenes in mushrooms. However, the avail-
ability of only limited number of commercial reference standards
of lanostanoids has diminished the number of triterpenes to be
analyzed (Adamec et al., 2009; Liu et al., 2011). It is not prac-
tical to expect every single lab to obtain reference standards by
going through laborious and time-consuming steps of isolating
and characterizing each individual lanostanoid. The aim of this
work is to develop a rapid and conclusive LC–MS method for
identiﬁcation of major triterpenes in Ganoderma mushrooms by
using the ganoderic acid samples we isolated.
MATERIALS AND METHODS
GENERAL EXPERIMENTAL PROCEDURES
Melting points were recorded on a Fisher-Johns melting point
apparatus. Optical rotations were recorded on a WZZ-1S auto-
matic polarimeter. UV spectra were recorded on a HP-8453 spec-
trophotometer. IR spectra were recorded on a Nicolet Magna
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FTIR-750 spectrometer. One- and two-dimensional NMR spectra
were recorded on a Bruker AMX 400 spectrometer. Acetonitrile
used in LC–MS analysis was supplied by Sigma-Aldrich Co. LLC.
Other reagents were all supplied by Sinopharm Chemical Reagent
Co. Ltd (Shanghai).
FUNGAL MATERIAL
ThemushroomofG.lucidumwasidentiﬁedbyProfessorGuanyun
Gu, School of Pharmacy, Fudan University, Shanghai, People’s
Republic of China. A voucher specimen (GL-9807) has been
depositedattheDepartmentofPharmacognosy,FudanUniversity,
Shanghai, People’s Republic of China.
IL-2, IL-4, AND IFN-γ ASSAYS
The sample was dissolved in a 0.4% DMSO solution, then incu-
bated with normal human peripheral blood mononuclear leuko-
cytes in a RPMI 1640 buffer containing 10% FBS, 50unit/mL
penicillin, and 50μg/mL streptomycin at 37˚C for 16h. Levels of
FIGURE 1 | Structures of oxygenated lanostanoids.
FIGURE 2 | High performance liquid chromatogram of the extract of G. lucidum.
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FIGURE 3 | Continued
IL-2, IL-4, and IFN-γ were measured using ELISA (Welker et al.,
1996; Ma et al.,2002).
HMG-CoA REDUCTASE ASSAY
A phosphate buffer solution contains 100mM potassium phos-
phate (pH 7.5), 8mM G-6-P, 1mM NADP, 4mM EDTA, 2mM
DTT, and 0.6U G-6-P-DH was prepared. The compound was
dissolved in a 1% DMSO solution and then pre-incubated with
microsomal protein in the phosphate buffer solution at 37˚C
for 15min. The reaction was started by the addition of 2.5μM
[14C]HMG-CoA reductase and the reaction was run at 37˚C for
15min. [14C]mevalonate was then quantiﬁed. It was determined
www.frontiersin.org May 2012 | Volume 3 | Article 85 | 3Qi et al. Method to identify ganoderma acids
FIGURE 3 | Continued
that compounds 1 and 2 inhibited HMG-CoA reductase with
IC50 =22.3 and 21.7μM, respectively (Heller and Gould, 1973;
Kubo and Strott, 1987; Li et al.,2006).
ACYL CoA-CHOLESTEROL ACYLTRANSFERASE ASSAY
The compound was dissolved in a 1% DMSO solution and
pre-incubated with Wistar rat hepatic microsomes in the 0.2-M
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FIGURE 3 | Mass spectra of the major ganoderic acids (7–20) in G. lucidum.
phosphate buffer at 37˚C for 15min. The reaction was started by
the addition of 18μM[ 14C]palmitoyl CoA-acyltransferase and
thereactionwasrunat37˚Cfor15min.[14C]cholesterolesterwas
then quantiﬁed. The inhibitory activities, IC50, of compounds 1
and 2 against CoA-acyltransferase were determined to be 5.5 and
47.3μM,respectively (Largis et al., 1989; Li et al.,2006).
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GANODERIC ACIDS
Ganoderma lucidum mushroom fruiting bodies (10kg) were
chipped and extracted with 20L of 95% ethanol at 80˚C three
times. After ﬁltering and removing of ethanol, the resulting
extract was applied onto a chromatographic silica gel column
and eluted with a chloroform/acetone gradient system, followed
by a reversed-phase C-18 column chromatographic run with
water/methanol.Theﬁnalpuriﬁcationof theganodericacidswere
accomplished by further high performance liquid chromatogram
(HPLC) separation and re-crystallization. Their structure were
identiﬁed and conﬁrmed by NMR and MS analyses (Ma et al.,
2002; Li et al., 2005, 2006). The reference standard solution of
each ganoderic acid was prepared by dissolving 1mg of ganoderic
acid in 1mL of methanol.
GANODERMA LUCIDUM EXTRACT
A G. lucidum extract (ReishiMax GLp™500mg) was introduced
into 25mL of ethyl acetate,sonicated for 30min,and ﬁltered. The
remaining insoluble material was extracted two more times as
above.Threeﬁltrateswerecombinedandthesolventwasremoved
under vacuum. The resulting residue was dissolved into 10mL of
methanol for LC–MS analysis.
LC–MS ANALYSIS
The HPLC system was controlled by an Agilent Mass-
Chrom data system. Chromatographic separation was per-
formed on a Phenomenex luna C-18 column (5μm,
250mm×4.6mm. I.D.) from Phenomenex Co. Ltd. A
step gradient solvent system was used: 0min CH3CN/0.1%
aqueous CH3COOH (25/75)→35min CH3CN/0.1% aque-
ous CH3COOH (35/65)→45min CH3CN/0.1% aqueous
CH3COOH (45/55)→90min CH3CN with a constant ﬂow rate
at 1.0mL/min. Column temperature was set at 30˚C controlled by
a column heater–cooler HP 1100. The elution was measured at
the wavelength range of 200–500nm by using a photodiode array
detector. Agilent triple-quadrupole ion-trap mass spectrometer
was equipped with an atmospheric pressure chemical ionization
interface(APCI).Themassspectrometerwasmass-calibratedwith
apolyglycolsolution.Inordertoachievemaximumsensitivitythe
massspectrometerconditionswere set at 450˚C of APCI tempera-
ture,60psi of nebulizing gas ﬂow rate,3500V of capillary voltage,
and 325˚C of capillary temperature. Full scam spectra from m/z
100 to m/z 1000Da were obtained in the positive ion mode.
RESULTS AND DISCUSSION
An HPLC method was developed to analyze the lipophilic part
of the commercial product ReishiMax GLp™. Ganoderic acids
were separated by a C-18 column with a step gradient sol-
vent system of CH3CN/0.1% aqueous CH3COOH. Figure 2
showed that the chromatogram of the column eluants mea-
sured at the wavelength of 252nm. Subsequent LC–MS analy-
sis with an ion-trap using APCI ionization technique was
followed.
The MS spectra of ganoderic acids 7–20 were established by
LC–MS. The APCI mass spectra of these compounds exhibited
peaks at m/z [M-nH2O+H]+ and [M-nH2O+H-130]+.T h e
loss of 130Da in the mass spectra represents the characteristic
cleavage of the αβ bond (C20–C22) from the C=O in the side
chain (Figure 3). The absence of these prominent fragments of
[M-nH2O+H-130]+ in ganoderenic acids B (11) and D (16),
and ganoderic acid DM (20) were expected due to the absence of
C=OatC23.HPLCretentiontimes(tR)of ganodericacids7–20,
alongwiththeirmassfragments,wereestablishedandlistedinthe
Table 1.
By comparison of the HPLC retention times and mass spec-
tra of the test sample and reference standards of ganoderic acids
(Table 1; Figure 3), the identities of 14 major peaks in the chro-
matogram of ReishiMax GLP™were conﬁrmed. Thus, one can
easilyusethisapproachbyperformingLC–MSanalysisonitssam-
ples and then comparing with the data in the Table 1 and mass
spectra in Figure 3 in this paper to establish the identity of each
chromatographic peak. Subsequently, only HPLC will be needed
for routine analysis of G. lucidum. This method has been used in
ourlaboratoriesandextractionfactorytoexaminethequalityand
quantity of the triterpene composition in incoming mushrooms,
crude extracts, ﬁnished goods, and competitor products. Our QC
Table 1 | Mass fragments and HPLC retention times of ganoderic acids (7–20).
Compound tR MW [M+H]+ [M-nH2O+H]+ [M-nH2O+H-130]+
7 14.3 532 – 515(26) 497(100) 479(25) 385(27) 367(85) 349(30)
8 17 .5 518 – 501(35) 483(100) 465(35) 371(35) 353(31) 335 (26)
9 20.1 530 531(4) 495(11) 477(22) 383(100) 365(50) 347(18)
10 22.1 532 – 497(31) 479(40) 461(50) 367(62) 349(100) 331(29)
11 22.8 514 515(2) 479(100) 461(50) –
12 24.3 516 – 499(20) 481(100) 463(45) 369(35) 351(27)
13 25.8 514 515(4) 497(7) 479(22) 367(100)
14 30.4 516 – 499(100) 481(53) 463(49) 387(47) 351(75)
15 31.1 572 573(4) 495(14) 477(35) 459(20) 383(51) 365(100)
16 37 .6 512 – 495(80) 477(100) –
17 40.4 514 515(4) 497(100) 479(60) 461(45) 427(45) 367(22) 349(22)
18 46.6 570 – 511(3) 493(8) 475(9) 447(11) 381(34) 363(100)
19 47 .3 514 515(2) 497(8) 479(18) 461(50) 403(37) 367(100)
20 70.2 468 469(100) – –
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lab has used the HPLC chromatograms as sample ﬁngerprints for
the cGMP compliant purpose. We believe this method could also
beaneffectivetoolforresearchersinfuturestudiesof otherrelated
Ganoderma species.
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